Certolizumab Pegol
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Jun 1, 2005 → Feb 1, 2012
NCT ID
NCT00175877About Certolizumab Pegol
Certolizumab Pegol is a phase 3 stage product being developed by UCB for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00175877. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03559686 | Pre-clinical | Active |
| NCT03559660 | Pre-clinical | Completed |
| NCT04740814 | Phase 1 | Completed |
| NCT04053881 | Pre-clinical | Completed |
| NCT03051217 | Phase 2/3 | Completed |
| NCT03020992 | Approved | Completed |
| NCT02597829 | Approved | UNKNOWN |
| NCT02552212 | Phase 3 | Completed |
| NCT02505542 | Phase 3 | Completed |
| NCT02365948 | Phase 1 | Completed |
| NCT02326298 | Phase 3 | Completed |
| NCT02326272 | Phase 3 | Completed |
| NCT02319642 | Phase 3 | Completed |
| NCT02154425 | Phase 1 | Completed |
| NCT02019602 | Phase 1 | Completed |
| NCT02293590 | Phase 2 | Completed |
| NCT01443364 | Approved | Completed |
| NCT01292265 | Phase 3 | Terminated |
| NCT01213017 | Phase 3 | Completed |
| NCT01053559 | Pre-clinical | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis